Tag: Alzheimer’s Disease International
-
Crisis and Opportunity: Cassava Sciences Still a Strong Buy
“With SAVA, once the pullback has exhausted itself, it’s a strong buy,” we noted on July 29. Since bottoming out around $65, the stock is back to $86.20 – and could refill its bearish gap around $140 with patience. In fact, if the company can continue to progress with its Alzheimer’s treatment, this stock could…